Sana Biotechnology (SANA) Competitors

Sana Biotechnology (NASDAQ:SANA) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.

Is SANA or GLPG more profitable?

Galapagos' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-84.22%	-44.97%
Galapagos	N/A	N/A	N/A

Does the MarketBeat Community favor SANA or GLPG?

Galapagos received 443 more outperform votes than Sana Biotechnology when rated by MarketBeat users. However, 63.89% of users gave Sana Biotechnology an outperform vote while only 63.84% of users gave Galapagos an outperform vote.

Company	Underperform	Outperform
Sana Biotechnology	Outperform Votes 23 63.89%	Underperform Votes 13 36.11%
Galapagos	Outperform Votes 466 63.84%	Underperform Votes 264 36.16%

Which has stronger valuation and earnings, SANA or GLPG?

Galapagos has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$283.26M	-$1.16	-1.42
Galapagos	$275.65M	5.90	$80.16M	N/A	N/A

Which has more risk and volatility, SANA or GLPG?

Sana Biotechnology has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Does the media prefer SANA or GLPG?

In the previous week, Sana Biotechnology had 11 more articles in the media than Galapagos. MarketBeat recorded 20 mentions for Sana Biotechnology and 9 mentions for Galapagos. Galapagos' average media sentiment score of 0.50 beat Sana Biotechnology's score of 0.11 indicating that Galapagos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	3 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galapagos	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer SANA or GLPG?

Sana Biotechnology currently has a consensus target price of $10.80, indicating a potential upside of 554.55%. Galapagos has a consensus target price of $25.33, indicating a potential upside of 2.73%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Galapagos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Galapagos	4 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Do insiders and institutionals believe in SANA or GLPG?

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by insiders. Comparatively, 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sana Biotechnology beats Galapagos on 8 of the 14 factors compared between the two stocks.